Inozyme Pharma’s (INZY) Outperform Rating Reaffirmed at Wedbush

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “outperform” rating reiterated by Wedbush in a research note issued to investors on Friday,RTT News reports. They presently have a $12.00 price target on the stock.

A number of other research firms also recently weighed in on INZY. Stifel Nicolaus assumed coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. HC Wainwright lifted their price objective on Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Raymond James started coverage on Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.25.

Inozyme Pharma Stock Down 28.6 %

INZY stock opened at $2.00 on Friday. Inozyme Pharma has a fifty-two week low of $1.97 and a fifty-two week high of $7.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The stock has a market capitalization of $128.48 million, a price-to-earnings ratio of -1.28 and a beta of 1.35. The business’s fifty day moving average price is $3.02 and its two-hundred day moving average price is $4.38.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. On average, equities analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Trading of Inozyme Pharma

Several institutional investors and hedge funds have recently modified their holdings of INZY. Deerfield Management Company L.P. Series C acquired a new position in shares of Inozyme Pharma during the second quarter worth $52,000. Virtu Financial LLC acquired a new position in Inozyme Pharma in the 3rd quarter worth about $64,000. Meeder Asset Management Inc. bought a new position in Inozyme Pharma in the second quarter valued at about $68,000. SG Americas Securities LLC acquired a new stake in shares of Inozyme Pharma during the third quarter valued at about $81,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Inozyme Pharma during the second quarter valued at about $84,000. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.